Journal of Microbial & Biochemical Technology

Incorporation of aluminum hydroxide and CpG ODN motifs into influenza vaccine formulation improves protective immunity against influenza virus challenge

12^th World Congress on Biotechnology and Microbiology

June 28-29, 2018 | Amsterdam, Netherlands

Mahbubeh Sadat Chalavi, Abbas Jamali and Sirus Saradar

Pasteur Institute of Iran, Iran

Posters & Accepted Abstracts: J Microb Biochem Technol

Abstract:

Introduction: Influenza is a major viral respiratory infection of humans. Vaccination is the most effective means for the prevention of influenza infection. Influenza whole-inactivated (WIV) vaccine is one of the commercially available vaccines that have been used for a number of years. Materials & Methods: In order to increase the vaccine efficiency, aluminum hydroxide (alum) was added as an adjuvant to WIV formulation. Aluminum adjuvant mainly induces a Th2 immune response. For balancing the immunity system and inducing the Th1 response CpG was added to mix of WIV and alum. A/PR/8/1934 H1N1 (PR8) influenza viruses were grown on MDCK cells. Virus purified by sucrose gradient ultracentrifugation and inactivated by Ultraviolet (UV). Mice were divided into four groups then immunized with different vaccines (WIV with or without aluminum hydroxide and CpG). Control mice were injected with phosphate buffer only. Four weeks after vaccination mice were anesthetized and challenged intranasally with 10 lethal doses (LD50) of PR8 virus. Mice were monitored twice a day for signs of clinical illness by weighing the animals and observing their appearance and activity for two weeks. Results: Our results showed that mice that received alum and CpG together adjuvant did not have weight loss in comparison to other groups. Whereas mice that received alum and CpG adjutants separately have shown significant weight loss. Conclusion: Formulation of alum and CpG adjuvant together with WIV vaccines could be protective against lethal challenge and more beneficial for achieving a better immune response.

Biography :

Mahbubeh Sadat Chalavi has completed her Bachelor’s degree from Azad Islamic University in Tehran North. She has obtained her Master’s degree in Microbiology from Azad Islamic of Zanjan. She has two years of experience in Pasteur Institute of Iran, experiencing vaccine development and drug diversity method by applying nano particle and adjuvant. She is currently pursuing her PhD from Qom University, Iran.

E-mail: cmabubeh@yahoo.com